Inhaled loxapine for acute agitation in schizophrenia and bipolar disorder

Future Neurology

Volumn 4, Issue 5, 2009, Pages 539-545

  Nordstrom, Kimberly ^a,b,c  

^a DENVER HEALTH MEDICAL CENTER   (United States)

^b Colorado West Regional Mental Health ^*  (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Agitation; Bipolar disorder; Loxapine; Schizophrenia; Staccato loxapine

Indexed keywords

AMOXAPINE; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; HALOPERIDOL; HISTAMINE H1 RECEPTOR; LOXAPINE; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; STACCATO; TIOTIXENE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; ZIPRASIDONE;

AEROSOL; AGITATION; BIPOLAR DISORDER; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HUMAN; HYPESTHESIA; INHALER; NAUSEA; NON INVASIVE PROCEDURE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STOMACH DISCOMFORT; SYSTEMIC CIRCULATION; THROAT IRRITATION; VOMITING;

EID: 75249104680     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/fnl.09.42     Document Type: Review

References (21)

1. De Fruyt J, Demyttenaere K: Rapid tranquilization: new approaches in the emergency treatment of behavioral disturbances. Eur. Psychiatry 19, 243-249 (2004).
2. Lindenmayer JP: The pathophysiology of agitation. J. Clin. Psychiatry 60(Suppl. 14), 5-10 (2000).
3. Swanson JW, Swartz MS et al.: A national study of violent behavior. Arch. Gen. Psychiatry 63, 490-499 (2006).
4. Tsuang MT, Tohen M: Textbook in Psychiatric Epidemiology (2nd Ed.). Wiley, NY, USA 343-479 (2002).
5. Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP: Expert consensus panel for behavioral emergencies 2005. The expert consensus guideline series treatment of behavioral emergencies. J. Psychiatr. Pract. 11(Suppl. 1), 5-108 (2005). ■ Reviews common treatments and provides expert consensus for guidelines in treatment.
6. Allen MH, Currier GW, Hughes DH, Docherty JP, Carpenter D, Ross R: Treatment of behavioral emergencies: a summary of the expert consensus guidelines. J. Psych. Pract. 9(1), 16-38 (2003).
7. National Collaborating Centre for Mental Health: Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. National Institute for Clinical Excellence (NICE), London, UK (2002).
8. Jennings A: The damaging consequences of violence and trauma: fact, discussion points, and recommendations for the behavioral health system. National Association of State Mental Health Program Directors, VA, USA 17-20 (2004).
9. Zisook S, Click MA: Evaluations of loxapine succinate in the ambulatory treatment of acute schizophrenic episodes. Int. Pharmacopsychiatry 15(6), 365-378 (1980).
10. Goldschmidt TJ, Burch EA: Use of loxapine to treat a patient with psychotic depression. Am. J. Psychiatry 139, 946-947 (1982).
11. Vanelle JM, Olie JP, Levy-Soussan P: New antipsychotics in schizophrenia: the French experience. Acta Psychiatr. Scand. Suppl. 380, 59-63 (1994).
12. Simpson GM, Cuculic Z: A double-blind comparison of loxapine succinate and trifluoperazine in newly admitted schizophrenic patients. J. Clin. Pharmacol. 16, 60-65 (1976).
13. Fruensgaard K , Wollenberg J, Hansen KM, Fensbo C, Sihm F: Loxapine versus perphenazine in psychotic patients. A double-blind, randomized, multicentre trial. Curr. Med. Res. Opin. 5(8), 601-607 (1978).
14. Chakrabarti A, Bagnall AM, Chue P et al.: Loxapine for schizophrenia. Cochrane Database Syst Rev. (4), CD001943 (2007). ■■ Timely review of all relevant studies of loxapine. Only studies with serious flaws were excluded.
15. Cassella JV, Houghton W, Spyker D, Munzar P, Mei L: Novel inhalation technology delivers intravenous-like pharmacokinetics of loxapine in healthy volunteers. Presented at: 47th Annual Meeting of New Clinic Drug Evaluation Unit (Division Center for Drug Evaluation Research). FL, USA 11-14 June 2007.
16. Kay SR, Fiszbein A, Opler LA: The positive and negative symptom scale for schizophrenia. Schizophr. Bull. 13, 261-276 (1987).
17. Guy W (Ed.): ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare Public Health Service Alcohol, Drug Abuse and Mental Health Administration, MD, USA (1976).
18. Swift RH, Harrigan EP, Cappelleri JC, Kramer D, Chandler LP: Validation of the behavioral activity rating scale (BARS): a novel measure of activity in agitated patients. J. Psychiatr. Res. 36(2), 87-95 (2002).
19. Allen MA, Munzar P, Spyker D, Cassella J: Inhaled loxapine significantly improves acute agitation in schizophrenic patients. Presented at: American College of Neuropharmacology. (2007).
20. News Release: Alexza's AZ-004 (Staccato® Loxapine) Phase III trial meets primary endpoint of treating acute agitation in schizophrenia patients. Alexza Pharmaceuticals. Mountain View, CA, USA Sept 02, 2008. www.alexza.com ■ Currently, the only way to review data on this medication is through news releases.
21. News Release: Alexza's AZ-004 (Staccato® Loxapine) meets primary endpoint of treating acute agitation in patients with bipolar disorder in Phase III trial. Alexza Pharmaceuticals. Mountain View, CA, USA Dec 09, 2008. www.alexza.com ■ Currently, the only way to review data on this medication is through news releases.